Interpretation of data regarding the men also presents pitfalls. According to the last observation carried foward, the men were more likely to respond to imipramine than sertraline—62.3% (43 of 69) versus 45.3% (73 of 161). The completer analysis for the men suggests that the response rates were 78.2% (43 of 55) for imipramine and 59.8% (73 of 122) for sertraline (χ2=4.9, df=1, p=0.03, with Yates’s correction). Although the results of the completer analysis are consistent with the possibility that men have a superior response to tricyclic antidepressants than to SSRIs, dozens of contrasts between tricyclic antidepressants and SSRIs have failed to show the superiority of tricyclic antidepressants for men. Therefore, one result favoring imipramine out of dozens of studies is consistent with a type I error (i.e., assuming an observed difference is valid when it is, in fact, a function of the anticipated error rate). Furthermore, the completer analysis suggests little difference between the sexes in response to SSRIs, i.e., 65.9% of women and 59.8% of men (χ2=0.28, df=1, p=0.59, with Yates’s correction). The greatest outlier in the completer analysis was the men’s high rate of response to the tricyclic antidepressant (78.2%); the other proportions of response were nearly equal (women: 62.9% for imipramine, 65.9% for sertraline; men: 59.8% for sertraline) (χ2=1.3, df=2, p=0.50).